ADVATE

DRUG10 trials

Conditions

Bone DiseaseHemophiliaHemophilia ASevere Hemophilia AVon Willebrand Disease (VWD)

Phase 1

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Start: 2015-06-30End: 2015-12-31Updated: 2016-02-17

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

CompletedNCT04864743

Jiangsu Gensciences lnc.Severe Hemophilia A

Start: 2021-06-22End: 2021-10-17Updated: 2023-09-08

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

CompletedNCT05251090

Jiangsu Gensciences lnc.Hemophilia A

Start: 2021-06-16End: 2022-05-09Updated: 2023-08-22

Phase 3

Prospective Biomarkers of Bone Metabolism in Hemophilia A

CompletedNCT02306694

Oregon Health and Science UniversityBone Disease, Hemophilia

Start: 2014-12-31End: 2018-04-16Updated: 2020-04-01

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

RecruitingNCT05582993

TakedaVon Willebrand Disease (VWD)

Start: 2024-11-06End: 2030-04-11Target: 24Updated: 2026-09-09

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

RecruitingNCT07129343

TakedaVon Willebrand Disease (VWD)

Start: 2025-10-13End: 2027-11-25Target: 20Updated: 2026-01-08

Phase 4

A Study of ADVATE in People With Hemophilia A in India

CompletedNCT04985682

Baxalta now part of ShireHemophilia A

Start: 2022-01-14End: 2023-02-10Updated: 2024-03-07

Unknown Phase

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

CompletedNCT02078427

Baxalta now part of ShireHemophilia A

Start: 2011-06-28End: 2024-01-16Updated: 2024-06-17

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A

NCT02282410

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHemophilia A

Start: 2014-12-31End: 2016-12-31Target: 15Updated: 2014-11-04

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

NCT03747653

Kaifeng Pharmaceutical (Group) Co., Ltd.Hemophilia A

Start: 2019-03-08End: 2020-05-31Target: 12Updated: 2020-05-08

2025-08-01

A Phase 3, Prospective, Open-Label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease

Blood2024-11-05

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

2024-08-202 citations

The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study

Therapeutic Advances in Hematology2024-01-015 citations

Chronic Disease Outcomes As Predictors of Quality of Life in Patients with Hemophilia Α: Data from the Real-World AHEAD International Study

Blood2023-11-02

P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A

HemaSphere2023-08-011 citations

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

Blood2020-11-043 citations

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Blood2019-11-131 citations

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Blood2019-11-131 citations

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.

2017-09-0129 citations